Published in Int J Clin Oncol on April 01, 2011
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol (2014) 1.13
Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report. Oncol Lett (2012) 0.81
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One (2015) 0.78
Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75
Paclitaxel-based chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy failure: a case series of 5 patients. Case Rep Oncol (2011) 0.75
Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett (2017) 0.75
Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol (2002) 4.15
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med (1997) 2.77
Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas (2004) 2.30
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol (2009) 2.23
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer (2009) 1.84
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer (2000) 1.56
Albumin-bound Paclitaxel: in metastatic breast cancer. Drugs (2006) 1.42
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol (2008) 1.39
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs (2000) 1.37
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology (2000) 1.29
Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol (2009) 1.22
Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol (2005) 1.18
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas (2008) 1.15
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer (2001) 1.11
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer (2006) 1.09
Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol (2007) 1.09
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol (2008) 0.88
Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma. Anticancer Drugs (2009) 0.75
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem (2002) 4.16
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas (2004) 2.30
Characteristics of printing company workers newly diagnosed with occupational cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 2.22
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 2.11
Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model. Inflamm Bowel Dis (2003) 2.09
Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol (2003) 1.70
Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas (2007) 1.54
Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A (2012) 1.53
Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet (2002) 1.44
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
The PMAIP1 gene on chromosome 18 is a candidate tumor suppressor gene in human pancreatic cancer. Dig Dis Sci (2008) 1.40
Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut (2010) 1.35
Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer (2008) 1.35
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis (2003) 1.30
Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun (2010) 1.28
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22
Current status of surgery for pancreatic cancer. Dig Surg (2007) 1.21
Thyroid hormone transporters: recent advances. Trends Endocrinol Metab (2002) 1.20
Clinicopathological aspects of small pancreatic cancer. Pancreas (2004) 1.18
Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2009) 1.18
Autoimmune pancreatitis with hepatic inflammatory pseudotumor. Pancreas (2005) 1.18
Predictive risk factors for clinically relevant pancreatic fistula analyzed in 1,239 patients with pancreaticoduodenectomy: multicenter data collection as a project study of pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2011) 1.18
Acute pancreatitis due to pancreatic arteriovenous malformation: 2 case reports and review of the literature. Pancreas (2006) 1.16
Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics (2010) 1.15
Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today (2011) 1.14
Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene (2003) 1.14
Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci (2007) 1.11
Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology (2008) 1.08
Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas (2005) 1.08
Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun (2005) 1.08
The Tohoku Medical Megabank Project: Design and Mission. J Epidemiol (2016) 1.08
Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res (2006) 1.07
miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol (2013) 1.07
PDZ binding motif-dependent localization of K+ channel on the basolateral side in distal tubules. Am J Physiol Renal Physiol (2004) 1.06
Optimization of glucose level to determine the stimulation index of isolated rat islets. Pancreas (2008) 1.06
Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas (2007) 1.04
Molecular cloning, expression and chromosomal localization of a novel human REG family gene, REG III. Gene (2004) 1.03
IFSO-APC consensus statements 2011. Obes Surg (2012) 1.03
New reconstructive procedure after intestinal resection for Crohn's disease: modified side-to-side isoperistaltic anastomosis with double Heineke-Mikulicz procedure. Dis Colon Rectum (2004) 1.03
Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2009) 1.01
Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol (2008) 1.01
PVA hydrogel sheet macroencapsulation for the bioartificial pancreas. Biomaterials (2004) 1.01
Intraductal papillary mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation. Abdom Imaging (2011) 1.01
Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. Cancer Res (2009) 1.00
Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol (2011) 1.00
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Ann Surg (2016) 1.00
Solid pseudopapillary neoplasms of the pancreas: an 18-year experience at a single Japanese Institution. Surg Today (2012) 1.00
LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. Int J Oncol (2009) 0.99
In vivo imaging demonstrates a time-line for new vessel formation in islet transplantation. Pediatr Transplant (2008) 0.99
Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2011) 0.98
Thermoelectricity in atom-sized junctions at room temperatures. Sci Rep (2013) 0.97
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol (2013) 0.97